Hence, the increased activity of FABP1 and the resulting enhanced intracellular trafficking of fatty acids in dyslipidemic condition may be shunting more detrimental fatty acids to storage and thereby promoting steatosis and NASH. This evidence concerns the gene FABP1 and metabolic dysfunction-associated steatohepatitis.